Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets boosted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 88.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 246,362 shares of the company's stock after acquiring an additional 115,351 shares during the period. BNP Paribas Financial Markets owned 0.24% of Intellia Therapeutics worth $5,063,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. ARK Investment Management LLC boosted its holdings in Intellia Therapeutics by 5.7% in the 3rd quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company's stock valued at $251,849,000 after purchasing an additional 659,651 shares in the last quarter. FMR LLC boosted its holdings in Intellia Therapeutics by 5.0% in the 3rd quarter. FMR LLC now owns 2,339,522 shares of the company's stock valued at $48,077,000 after purchasing an additional 111,104 shares in the last quarter. Federated Hermes Inc. boosted its holdings in Intellia Therapeutics by 19.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company's stock valued at $51,494,000 after purchasing an additional 371,189 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Intellia Therapeutics by 8.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company's stock valued at $29,648,000 after purchasing an additional 98,865 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Intellia Therapeutics by 4.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 827,545 shares of the company's stock valued at $17,006,000 after purchasing an additional 37,714 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Stifel Nicolaus lowered their price objective on Intellia Therapeutics from $80.00 to $64.00 and set a "buy" rating on the stock in a report on Wednesday, September 11th. Oppenheimer decreased their price target on Intellia Therapeutics from $70.00 to $60.00 and set an "outperform" rating on the stock in a research note on Monday, November 11th. JPMorgan Chase & Co. decreased their price target on Intellia Therapeutics from $61.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, August 12th. Canaccord Genuity Group reissued a "buy" rating and set a $90.00 price target on shares of Intellia Therapeutics in a research note on Tuesday, November 19th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $54.00 price target on shares of Intellia Therapeutics in a research note on Thursday, September 19th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $54.94.

Intellia Therapeutics Price Performance

NTLA traded up $0.25 during trading on Wednesday, hitting $14.90. The company's stock had a trading volume of 701,098 shares, compared to its average volume of 1,743,771. The firm's 50 day moving average price is $17.00 and its 200-day moving average price is $21.19. The stock has a market cap of $1.52 billion, a PE ratio of -2.69 and a beta of 1.76. Intellia Therapeutics, Inc. has a twelve month low of $12.82 and a twelve month high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to analyst estimates of $8.28 million. The company's revenue was down 24.1% on a year-over-year basis. During the same quarter last year, the firm posted ($1.38) earnings per share. Equities analysts anticipate that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current year.

Insider Buying and Selling at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,012 shares of the company's stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the sale, the chief accounting officer now directly owns 47,012 shares in the company, valued at $893,698.12. This represents a 4.10 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 3.20% of the stock is currently owned by insiders.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.